Can women get androgenetic alopecia?

Yes — androgenetic alopecia affects up to 40% of women by menopause, making it the most common cause of hair loss in women as well as men. The hormonal driver is the same (DHT), but the pattern differs: women typically experience diffuse thinning across the crown with a widening centre part rather than complete baldness. In women, hormonal blood work is particularly important because an underlying condition such as PCOS or post-menopausal androgen excess may be contributing and is independently treatable.

Is androgenetic alopecia permanent?

Without treatment, androgenetic alopecia is progressive and the follicular changes are permanent — follicles that have been fully miniaturized over many years cannot be reactivated. However, starting treatment early can significantly slow or halt progression, and in some cases stimulate partial regrowth. Minoxidil and finasteride work best when begun before affected follicles have stopped producing hair entirely, which is why clinicians consistently recommend not waiting.

Does androgenetic alopecia skip generations?

Not reliably. Androgenetic alopecia is polygenic, meaning multiple genes inherited from both parents influence risk — it does not follow a simple dominant or recessive pattern. Having a parent or grandparent with significant hair loss raises your risk, but the condition can appear without a strong family history, and some people with extensive family history are minimally affected. Genetic testing for androgenetic alopecia risk is not currently recommended in Canadian clinical practice.

Can stress make androgenetic alopecia worse?

Yes. Significant physical or psychological stress can trigger telogen effluvium — a separate condition in which large numbers of hairs simultaneously shift into the resting phase and shed, typically 2–3 months after the stressor. When telogen effluvium is superimposed on existing androgenetic alopecia, the combined effect on hair density can be dramatic and distressing. Managing stress, sleep, and nutritional deficiencies (particularly iron and ferritin) is an important part of a comprehensive hair loss management plan.

Is minoxidil or finasteride covered by provincial drug plans in Canada?

Coverage varies by province and individual plan. Topical minoxidil is available over the counter at most Canadian pharmacies without a prescription and is generally not covered by provincial formularies because it is an OTC product. Oral minoxidil and finasteride require a prescription; coverage under provincial drug benefit programs (such as Ontario's ODB or BC PharmaCare) depends on the listed indication and the patient's eligibility category. Patients with private insurance should check their formulary, as coverage for hair loss medications is inconsistent. A pharmacist or prescribing clinician can help identify the most cost-effective option.

Androgenetic alopecia — Glossary

What it is

Androgenetic alopecia is the most common cause of progressive hair loss worldwide, affecting roughly 50% of men by age 50 and up to 40% of women by the time they reach menopause. Also called male pattern baldness or female pattern hair loss (FPHL), androgenetic alopecia is a hormonally driven condition in which scalp hair follicles gradually miniaturize in response to dihydrotestosterone (DHT), eventually producing finer, shorter hairs before ceasing to grow altogether.

In men, hair loss follows a recognizable sequence — receding temples, thinning crown, and eventual merging of the two areas — classified on the Norwood scale. In women, the pattern is typically diffuse thinning across the top of the scalp with a widening centre part and preservation of the frontal hairline, classified on the Ludwig scale. Complete baldness in women is uncommon. While the condition poses no direct medical danger, it carries a significant psychological burden for many patients and worsens steadily without treatment. Canadian patients can access diagnostic workup through LifeLabs or Dynacare and prescription therapies through family physicians, dermatologists, or virtual-care platforms.

Feature	Men (male pattern baldness)	Women (female pattern hair loss)
Typical onset	Late teens to 20s	Perimenopausal or later
Pattern	Receding hairline + crown thinning (Norwood scale)	Diffuse crown thinning, wide part (Ludwig scale)
Frontal hairline	Usually recedes	Usually preserved
Complete baldness	Common in advanced stages	Rare
First-line treatment	Minoxidil, finasteride	Minoxidil, spironolactone

Causes and mechanism

Androgenetic alopecia arises from the intersection of genetic predisposition and androgen activity. The enzyme 5-alpha reductase converts testosterone into DHT. In genetically susceptible individuals, scalp follicles carry androgen receptors that are highly sensitive to DHT; prolonged exposure causes progressive follicular miniaturization until the follicle becomes dormant.

The condition is polygenic — risk genes are inherited from both parents, not just the maternal grandfather as popular belief holds. Key contributing factors include:

Androgens: In men, circulating testosterone drives DHT production. In women, elevated androgens from polycystic ovary syndrome (PCOS), adrenal disorders, or post-menopausal hormonal shifts can accelerate loss.
Estrogen decline: Estrogen normally counterbalances androgen effects on follicles. Its fall at menopause often unmasks or accelerates androgenetic alopecia in women.
Age: Cumulative DHT exposure increases with age, which is why prevalence rises steadily after puberty.

Symptoms and diagnosis

Hair loss in androgenetic alopecia develops gradually. In men, the earliest sign is usually temporal recession forming an "M" shape, followed by crown thinning. In women, the centre part widens and overall density at the crown decreases; shedding during washing or brushing is often the first noticed symptom. Affected hairs become progressively finer and lighter before disappearing.

Diagnosis is primarily clinical, based on pattern recognition and family history. In women — and in men with atypical presentations — laboratory investigations help rule out contributing causes:

Serum androgens (total and free testosterone, DHEA-S) — to identify hyperandrogenism
SHBG — low levels increase androgen bioavailability
TSH — thyroid dysfunction independently causes hair loss
Ferritin and iron studies — iron deficiency frequently coexists and worsens androgenetic alopecia
Scalp biopsy — occasionally used when the diagnosis is ambiguous

These tests are available through LifeLabs and Dynacare across most Canadian provinces; provincial coverage varies by indication.

Treatment options

Treatment slows progression and, when started early, can stimulate partial regrowth. Follicles that have been fully dormant for years cannot be reactivated, so earlier intervention consistently produces better outcomes.

Minoxidil (topical or oral): The most widely used first-line option for both sexes. It prolongs the anagen (growth) phase and increases follicular blood flow. Topical formulations (2% or 5%) are applied once or twice daily; low-dose oral minoxidil is increasingly prescribed for its convenience and comparable efficacy. A 2017 meta-analysis in the Journal of the American Academy of Dermatology found minoxidil significantly more effective than placebo for both sexes.

Finasteride (oral): A 5-alpha reductase inhibitor that reduces DHT production by approximately 70% at the standard 1 mg daily dose. Health Canada has approved finasteride 1 mg for men with androgenetic alopecia. It is used off-label in post-menopausal women in some cases. It is contraindicated in women who are or may become pregnant due to risk of fetal harm.

Dutasteride: Blocks both isoforms of 5-alpha reductase, making it more potent than finasteride. Used in men who do not respond adequately to finasteride; off-label for this indication in Canada.

Spironolactone: An anti-androgen used in women, particularly those with elevated androgens or PCOS. It blocks DHT's effect at the follicle receptor level.

Low-level laser therapy (LLLT): A non-invasive device-based option with modest supporting evidence; generally considered adjunctive rather than primary therapy.

Hair transplant surgery: A permanent option for patients with sufficient donor hair, most effective when combined with ongoing medical therapy to prevent further loss in non-transplanted areas.

Canadian patients seeking prescription treatment can consult a family physician, dermatologist, or virtual-care platforms such as Felix, Maple, Cleo, or Phoenix, which offer asynchronous or same-day consultations for hair loss medications.

When to see a clinician in Canada

Seek assessment if you notice a widening part, receding hairline, or crown thinning that has been progressing over several months; if shedding during washing or brushing has increased noticeably; or if hair loss is causing significant distress. Women who experience hair loss alongside irregular periods, excess facial or body hair, or acne should be assessed promptly, as these signs may indicate an underlying hormonal condition such as PCOS that warrants its own treatment. Starting therapy earlier in the course of hair loss preserves more follicles and produces better long-term density outcomes.

Limitations and open questions

Research is still emerging on the optimal dosing and long-term safety profile of oral low-dose minoxidil, particularly in women; most published trials are short-term and relatively small. The role of dutasteride in women has not been well studied in randomized controlled trials. Health Canada has not issued specific guidance on off-label use of finasteride or dutasteride in women with androgenetic alopecia, leaving prescribers to rely on international guidelines and clinical judgment. The association between androgenetic alopecia in men and cardiovascular risk (including coronary artery disease and insulin resistance) is noted in the literature but causality has not been established, and routine cardiovascular screening based solely on hair loss pattern is not currently recommended in Canadian clinical guidelines. The psychological impact of androgenetic alopecia is well documented but remains undertreated; evidence-based mental health support pathways specific to hair loss are not yet standardized in Canadian primary care.

Androgenetic alopecia